Lanreotide
Also known as: Somatuline, Somatuline Depot
Key Facts: Lanreotide
- Category
- Hormonal
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Acromegaly and GEP-NETs
- Administration
- Deep subcutaneous injection
- Typical Dose
- 60-120 mg every 4 weeks
- Frequency
- Every 4 weeks (deep SC)
- Evidence Level
- FDA Approved
- Duration
- Long-term / chronic use
What to Expect
A long-acting somatostatin analog similar to octreotide. FDA approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.
Mechanism of Action
Lanreotide binds preferentially to SST2 and SST5 somatostatin receptors. Inhibits GH secretion, reduces IGF-1 levels, and has antiproliferative effects on neuroendocrine tumor cells. Self-injectable deep SC formulation.
Research Summary
CLARINET trial demonstrated tumor control in GEP-NETs. Noninferior to octreotide for acromegaly. Unique self-injectable deep subcutaneous formulation improves convenience. Extended dosing interval available.
Dosing Information
Typical Dosingⓘ
Community experience
60-120 mg every 4 weeks
60-120 mg per injection
Every 4 weeks (deep SC)
Long-acting somatostatin analog. Somatuline Depot. Deep subcutaneous injection.
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
60-120 mg deep SC every 4 weeks
Extended interval dosing possible
Duration
Long-term / chronic use
Administration
Deep subcutaneous injection
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Diarrhea
- ●Abdominal pain
- ●Nausea
- ●Injection site reactions
- ●Gallstones
- ●Hyperglycemia or hypoglycemia
- ●Bradycardia
- ●FDA approved (Somatuline)
References
Related Peptides
Peptides commonly compared with Lanreotide or used in similar applications.
Gonadorelin
FDAA synthetic version of gonadotropin-releasing hormone. Used diagnostically and therapeutically for various reproductive and hormonal conditions.
HormonalPegvisomant
FDAA GH receptor antagonist that blocks growth hormone action. Used for acromegaly when surgery and somatostatin analogs fail to normalize IGF-1.
HormonalMacimorelin
FDAAn oral ghrelin mimetic used to diagnose adult growth hormone deficiency. The first FDA-approved oral GH stimulation test.
HormonalOxytocin
FDAA naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.
HormonalLeuprolide
FDAA GnRH agonist that suppresses testosterone and estrogen production. FDA approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
HormonalDesmopressin
FDAA synthetic analog of vasopressin (ADH) used for diabetes insipidus, bedwetting, and bleeding disorders. Does not cause vasoconstriction like natural vasopressin.
HormonalWant updates on Lanreotide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.